The efficiency of intraperitoneal high-dose immunoglobulin in experimental nephrotic syndrome


Erisir S., Akbas H., Koyun M., Akman S.

PEDIATRIC NEPHROLOGY, vol.21, no.1, pp.39-45, 2006 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 21 Issue: 1
  • Publication Date: 2006
  • Doi Number: 10.1007/s00467-005-2046-y
  • Journal Name: PEDIATRIC NEPHROLOGY
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.39-45
  • Keywords: adriamycin-induced nephrotic syndrome, rat, immunoglobulin, treatment, ADRIAMYCIN-INDUCED NEPHROPATHY, INTRAVENOUS IMMUNE GLOBULIN, HENOCH-SCHONLEIN PURPURA, MEMBRANOUS NEPHROPATHY, SUPEROXIDE-DISMUTASE, RATS, ALPHA, EXPRESSION, THERAPY, MODEL
  • Akdeniz University Affiliated: Yes

Abstract

Although it has been reported that high-dose immunoglobulin has beneficial effects in chronic glomerulonephritis, it is not known whether it is effective in the treatment of idiopathic nephrotic syndrome. We have investigated the effects of intraperitoneal immunoglobulin in adriamycin-induced nephrotic syndrome. Adriamycin (2 mg kg(-1) per dose) was given intravenously to sixteen Wistar albino rats (eight control and eight treatment rats) on day 1 and at week 3. At week 5 intraperitoneal immunoglobulin (1 g kg(-1) per dose) was given to the treatment group on two consecutive days whereas the control group received intraperitoneal saline solution. In both treatment and control groups urinary protein excretion was significantly elevated after administration of adriamycin (P=0.018). Urinary protein excretion, serum albumin, and triglyceride levels in the two groups were not significantly different after 5, 8, 12, and 16 weeks. Serum creatinine levels were higher and creatinine clearance was significantly lower in the control group in week 16 (P=0.001 and P=0.049, respectively). Glomerular sclerosis index was significantly lower in the treatment group (P=0.012). Although intraperitoneal high-dose immunoglobulin did not reverse biochemical results, it is encouraging that glomerular sclerosis index was significantly lower in the treatment group.